Bank of New York Mellon Corp Buys 20,659 Shares of GSK plc (NYSE:GSK)

Bank of New York Mellon Corp lifted its stake in GSK plc (NYSE:GSK - Free Report) by 2.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 974,051 shares of the pharmaceutical company's stock after purchasing an additional 20,659 shares during the period. Bank of New York Mellon Corp's holdings in GSK were worth $32,942,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Indiana Trust & Investment Management Co raised its stake in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust purchased a new position in GSK during the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. boosted its position in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Sierra Ocean LLC bought a new stake in shares of GSK during the 4th quarter valued at $32,000. 15.74% of the stock is owned by institutional investors.

GSK Price Performance

Shares of NYSE:GSK traded up $0.45 during mid-day trading on Monday, reaching $40.50. The stock had a trading volume of 499,431 shares, compared to its average volume of 4,225,569. The company has a market cap of $83.94 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The business's 50 day moving average price is $35.47 and its 200 day moving average price is $37.14. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93.

Remove Ads

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.88%. The ex-dividend date of this dividend is Friday, February 21st. GSK's dividend payout ratio (DPR) is presently 98.74%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on GSK shares. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and lowered their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.